Nurix Therapeutics Inc

{ "date": [ "202611", "202711", "202811", "202911", "203011" ], "revenue_estimate": [ 54.44, 77.18, 134.84, 214.6, 414.87 ], "ebit_estimate": [ -332.76, -328.37, -303.4, -292.46, -39.24 ], "ebitda_estimate": [ -331.95, -370.74, -287.41, null, null ], "net_income_estimate": [ -310.11, -306.23, -267.43, -255.33, -65.91 ], "per_share_eps_estimate": [ -2.84, -2.59, -2.06, -1.87, -0.72 ], "eps_nri_estimate": [ -2.77, -2.56, -2.06, -1.87, -0.72 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 2.66, 2.08, 2.16, null, null ], "pretax_income_estimate": [ -312.84, -311.04, -271.95, -255.33, -58.76 ], "operating_cash_flow_per_share_estimate": [ -2.49, -2.5, -1.58, null, null ], "roa_estimate": [ -59.4, -83.8, -34, null, null ], "roe_estimate": [ -73.73, -105.63, -100.6, null, null ], "gross_margin_estimate": [ 100, 100, 96.81, 95.07, 94 ], "operating_cash_flow_estimate": [ -276.04, -277.16, -175.51, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 11.79, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 11.92, "future_eps_nri_estimate_growth": 11.79, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -25.42, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -28.14, "future_gross_margin_estimate_growth": -0.97, "future_operating_cash_flow_per_share_estimate_growth": 16.44 }

{ "date": [ "202608", "202611", "202702", "202705", "202708", "202711" ], "revenue_estimate": [ 17.21, 19.46, 15.32, 15.32, 15.82, 16.88 ], "ebit_estimate": [ -80.68, -75.05, -82.38, -84.31, -86.6, -87.97 ], "ebitda_estimate": [ -85.97, -87.9, null, null, null, null ], "net_income_estimate": [ -75.15, -68.46, -76.92, -78.35, -81.35, -83.46 ], "per_share_eps_estimate": [ -0.69, -0.62, -0.69, -0.7, -0.72, -0.72 ], "eps_nri_estimate": [ -0.67, -0.6, -0.69, -0.7, -0.72, -0.72 ], "dividend_estimate": [ null, null, null, null, null, null ], "book_value_per_share_estimate": [ 2.32, 1.34, null, null, null, null ], "pretax_income_estimate": [ -75.86, -69.26, -76.92, -78.35, -81.35, -83.46 ], "operating_cash_flow_per_share_estimate": [ -0.65, -0.63, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null ], "roe_estimate": [ -83.85, -73.32, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100, 100 ], "operating_cash_flow_estimate": [ -72.21, -69.98, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 11.79, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 11.92, "future_eps_nri_estimate_growth": 11.79, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -25.42, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -28.14, "future_gross_margin_estimate_growth": -0.97, "future_operating_cash_flow_per_share_estimate_growth": 16.44 }